Friday , May 7 2021

New Alzheimer's vaccine could reduce dementia cases by half & # 39;

(KUTV) – A DNA vaccine tested on mice, which could have a major impact on the development of Alzheimer's disease, may soon be on clinical trials in humans.

According to a new study published in Alzheimer's research and therapy, the experimental vaccine reduced the accumulation of two types of toxic proteins that are believed to be Alzheimer's disease, without any side effects such as the brain island.

The ten-year research project was led by Peter O & # 39; Donnell Jr. Brain Institute, University of Texas Southwestern.

"If the disease could have been delayed for five years, it would be enormous for patients and their families," said Dr. Doris Lambracht-Washington, senior author of the study. "The number of cases of dementia could be reduced by half."

Earlier promising vaccines caused a "serious brain island" in some patients.

The vaccine that comes from the skin activates the immune response that reduces the formation of harmful tauvases and beta-amyloids.

"This study is a culmination of a decade of research that has repeatedly shown that this vaccine can efficiently and safely target animal models what we think can cause Alzheimer's disease," said Dr. Roger Rosenberg, founder director of the Alzheimer's Disease Center at UT Southwestern. "I believe we are getting closer to testing this therapy for people."

So far, it has been safely tested in three mammals and could soon study the way to clinical trials.

"The vaccine is on a short list of promising antibody therapies aimed at protecting both types of proteins that kill brain cells as they spread into deadly plaques and tangles in the brain of patients with Alzheimer's disease," the UT Southwestern statement said.

Alzheimer progressively exacerbates the brain in about 5.7 million US patients. This number is expected to double by 2050, according to the Centers for Disease Control and Prevention (CDC).

There is currently no effective treatment for Alzheimer's disease.

A new study suggests that the vaccine is the most effective in patients with high levels of "tau and amyloid stored in the brain", but before the patient develops Alzheimer's disease completely.

"The longer you wait, the less likely it will be," said Dr. Rosenberg. "When these plates and tangles are formed, it may be too late."

Source link